Ayşe KIRBAŞ, Korkut DAĞLAR, Nuri DANIŞMAN

Non-Invasive Prenatal Testing for Aneuploidy: A Review of the Literature

Aneuploidy is one of the leading causes of perinatal deaths and childhood handicaps. An important issue that has led to heated debates in the agenda of maternal-fetal medicine and that has been widely investigated in recent years is 'the isolation of fetal deoxyribonucleic acid (DNA) from maternal blood. It is agreed that fetal DNA can be used in fetal aneuploidy screening and in predicting some pregnancy complications that are considered to be of placenta-based such as preeclampsia and preterm labor. The fetal DNA testing of maternal blood is regarded as an advanced screening test and generally named as 'noninvasive prenatal test' (NIPT). In this meta-study, we will review the accumulated data on the increasing clinical use of NIPT in perinatology as well as the other presently used conventional noninvasive aneuploidy screening methods.

PDF

___

1. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011;31(1):7-15.

2. Gil MM, Akolekar R, Quezada MS, Bregant B, Nicolaides KH. Analysis of Cell-Free DNA in Maternal Blood in Screening for Aneuploidies: Meta-Analysis. Fetal Diagn Ther. 2014:41(3):26-32.

3. Ashoor G, Syngelaki A, Poon LCY, Rezende JC, Nicolaides KH. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013;31(1):237-43.

4. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012;206(4):322.e1-5.

5. American College of Obstetricians and Gynecologists ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007;109(1):217- 27.

6. Spencer K, Nicolaides KH. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. BJOG. 2003;110(3):276-80.

7. Madsen HN, Ball S, Wright D, Tørring N, Petersen OB, Nicolaides KH, Spencer K. A reassessment of biochemical marker distributions in trisomy 21 affected and unaffected twin pregnancies in the first trimester Ultrasound Obstet Gynecol. 2011;37(1):38-47.

8. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies; a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG. 2000;107(10):1271-5.

9. Spencer K, Ong C, Skentou H, Liao AW, H Nicolaides K. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn. 2000;20(5):411-6.

10. Spencer K, Tul N, Nicolaides KH. Maternal serum free beta hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn. 2000;20(5):390-4.

11. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. Br Med J. 1992;304(6831):867-9.

12. Nicolaides KH, Snijders RJM, Gosden RJM, Berry C, Campbell S. Ultrasonographically detectable markers of fetal chromosomal abnormalities. Lancet. 1992;340(8821):704-7.

13. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free ?- human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol. 1999;13(4):231-7.

14. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol. 2004;191(1):45-67.

15. Nicolaides KH, Snijders RJ, Cuckle HS. Correct estimation of parametersfor ultrasound nuchal translucency screening. Prenat Diagn. 1998;18(5):519-23.

16. Spencer K, Bindra R, Nix ABJ, Heath V, Nicolaides KH. Delta- NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol. 2003;22(2):142-8.

17. Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol. 2009;33(3):259-64.

18. Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11 + 0-13 + 6 weeks of gestation. Ultrasound Obstet Gynecol. 2009;33(3):18-22.

19. Papaioannou GK, Syngelaki A, Maiz N, Ross JA, Nicolaides KH. Sonographic markers of aneuploidies at 6-10 weeks of gestation. Early Hum Dev. 2011;87(7):453- 6.

20. Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free ?-hCG and pregnancy-associated plasma protein-A. Hum Reprod. 2008;23(9):1968-75.

21. Hansen M, Kurinczuk JJ, Bower C, Webb S. The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. N Engl J Med. 2002;346(10):725-30.

22. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Munson ML. Births: final data for 2002. Natl Vital Stat Rep. 2003;52(10):1-113.

23. Gleicher N, Oleske DM, Tur-Kaspa I, Vidali A, Karande V. Reducing the risk of highorder multiple pregnancy after ovarian stimulation with gonadotropins. N Engl J Med. 2000;343(1):2-7.

24. Sebire NJ, Snijders RJM, Hughes K, Sepulveda W, Nicolaides KH. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. BJOG. 1996;103(10):999-1003.

25. Spencer K, Nicolaides KH. First trimester prenatal diagnosis of trisomy 21 in discordant twins using fetal nuchal translucency thickness and maternal serum free beta-hCG and PAPP-A. Prenat Diagn. 2000;20(8):683-4.

26. Spencer K, Kagan KO, Nicolaides KH. Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers. Prenat Diagn. 2008;28(1):49-52.

27. Sebire NJ, Hughes K, D'Ercole C, Souka A, Nicolaides KH. Increased fetal nuchal translucency at 10-14 weeks as a predictor of severe twin-to twin transfusion syndrome. Ultrasound Obstet Gynecol. 1997;10(2):86-9.

28. Lo YM, Lo ES, Watson N, Noakes L, Sargent IL, Thilaganathan B, Wainscoat JS. Two-way cell traffic between mother and fetus: biologic and clinical implications. Blood. 1996;88(11):4390-5.

29. Lo YMD. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485-7.

30. Bianchi DW. Circulating fetal DNA: its origin and diagnostic potential-a review. Placenta. 2004;25 Suppl A:S93-S101.

31. Wright CF, Burton H. The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Hum Reprod Update. 2009;15(1):139-51.

32. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma Am J Hum Genet. 1999;64(1):218-24.

33. Gauthier VJ, Tyler LN, Mannik M. Blood clearance kinetics and liver uptake of mononucleosomes in mice. J Immunol. 1996;156(3):1151-6.

34. Emlen W, Burdick G. Clearance and organ localization of small DNA anti-DNA immune complexes in mice. J Immunol. 1988;140(6):1816-22.

35. Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, Lu V, McCullough R, McCarthy E, Nygren AO, Dean J, Tang L, Hutchison D, Lu T, Wang H, Angkachatchai V, Oeth P, Cantor CR, Bombard A, van den Boom D. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol. 2011;204(3):205.e1-e11.

36. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Deciu C, Grody WW, Nelson SF, Canick JA. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med. 2011;13(11):913-20.

37. Ashoor G, Poon L, Syngelaki A, Mosimann B, Nicolaides KH. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: effect of maternal and fetal factors. Fetal Diagn Ther. 2012;31(4):237-43.

38. Osborne CM, Hardisty E, Devers P, Kaiser-Rogers K, Hayden MA, Goodnight W, Vora NL. Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease. Prenat Diagn. 2013;33(6):609-11.

39. Liao GJ, Gronowski AM, Zhao Z. Non-invasive prenatal testing using cell-free fetal DNA in maternal circulation. Clin Chim Acta. 2014;20(428):44-50.

40. Bischoff FZ, Lewis DE, Simpson JL. Cell free fetal DNA in maternal blood: Kinetics, source and structure. Human Reproduction Update. 2005;11(1):59-67.

41. Hristoskova S, HolzgreveW, Hahn S. More than one-half of the erythroblasts in the fetal circulation and cord blood are TUNEL positive. Clinical Chemistry. 2001;47(10):1870-1.

42. Sekizawa A, Samura O, Zhen DK, Falco V, Farina A, Bianchi DW. Apoptosis in fetal nucleated erythrocytes circulating in maternal blood. Prenatal Diagnosis. 2000;20(11):886-9.

43. Devaney SA, Palomaki GE, Scott JA, Bianchi DW. Noninvasive fetal sexdetermination using cell-free fetal DNA a systematic review and meta-analysis. JAMA. 2011;306(6):627-36.

44. Rijnders RJP, van der Luijt RB, Peters EDJ, Goeree JK, Van Der Schoot CE, Ploos Van Amstel JK, Christiaens GC. Earliest gestational age for fetal sexing in cell-free maternal plasma. Prenatal Diagnosis. 2003;23(13):1042-4.

45. Norbury G, Norbury CJ. Non-invasive prenatal diagnosis of single gene disorders: How close are we? Semin Fetal Neonatal Med. 2008;13(2):76-83.

46. Legler TJ, Muller SP, Haverkamp A, Grill S, Hahn S. Prenatal RhD testing: a review of studies published from 2006 to 2008. Transfus Med Hemother. 2009;36(3):189-98.

47. Zhong XY, Holzgreve W, Hahn S. The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy. 2002;21(1):77-83.

48. Leung TN, Zhang J, Lau TK, Chan LY and Lo YM. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem. 2001;47(1):137-9.

49. Levine RJ, Qian C, Leshane ES, Yu KF, England LJ, Schisterman EF, Wataganara T, Romero R, Bianchi DW. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol. 2004;190(3):707-13.

50. Rolnik DL, O'Gorman N, Fiolna M, van den Boom D, Nicolaides KH, Poon LC. Maternal plasma cell-free DNA in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2015;45(1):106-11.

51. Farina A, LeShane ES, Romero R, Gomez R, Chaiworapongsa T, Rizzo N, Bianchi DW. High levels of fetal cell-free DNA in maternal serum: a risk factor for spontaneous preterm delivery. Am J Obstet Gynecol. 2005;193(2):421-5.

52. Illanes S, Gomez R, Fornes R, Figueroa-Diesel H, Schepeler M, Searovic P, Serra R, Perez A, Nien JK. Free fetal DNA levels in patients at risk of preterm labour. Prenat Diagn. 2011;31(11):1082-5.

53. Quezada MS, Francisco C, Dumitrascu-Biris D, Nicolaides KH, Poon LC. Fetal fraction of cell-free DNA in maternal plasma in the prediction of spontaneous preterm delivery. Ultrasound Obstet Gynecol. 2015;45(1):101-5.

54. Lo YMD, Lau TK, Zhang J, Leung TN, Chang AM, Hjelm NM, Elmes RS, Bianchi DW. Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21. Clin Chem. 1999;45(10):1747-51.

55. Sparks AB, Wang ET, Struble CA, Barrett W, Stokowski R, McBride C, Zahn J, Lee K, Shen N, Doshi J, Sun M, Garrison J, Sandler J, Hollemon D, Pattee P, TomitaMitchell A, Mitchell M, Stuelpnagel J, Song K, Oliphant A. Selective analysis of cellfree DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn. 2012;32(31):3-9.

56. Peters DG, Yatsenko SA, Surti U, Rajkovic A. Recent advances of genomic testing in perinatal medicine. Semin Perinatol. 2015;39(1):44-54.

57. Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2015;45(3):249-66.

58. del Mar Gil M, Quezada MS, Bregant B, Syngelaki A, Nicolaides KH. Cell-free DNA analysis for trisomy risk assessment in first-trimester twin pregnancies. Fetal Diagn Ther. 2014;35(3):204-11.

59. Struble CA, Syngelaki A, Oliphant A, Song K, Nicolaides KH. Fetal Fraction Estimate in Twin Pregnancies Using Directed Cell-Free DNA Analysis. Fetal Diagn Ther. 2014;35(3):199-203.

60. Sehnert AJ, Rhees B, Comstock D, Comstock D, de Feo E, Heilek G, Burke J, Rava RP.l. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cellfree fetal DNA from maternal blood. Clin Chem. 2011;57(7):1042-9.

61. Canick JA, Kloza EM, Lambert-Messerlian GM, Haddow JE, Ehrich M, van den Boom D, Bombard AT, Deciu C, Palomaki GE. DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations. Prenat Diagn. 2012;32(8):730-4.

62. Lau TK, Jiang F, Chan MK, Zhang H, Lo PS, Wang W. Non-invasive prenatal screening of fetal Down syndrome by maternal plasma DNA sequencing in twin pregnancies. J Matern Fetal Neonatal Med. 2013;26(4):434-7.

63. Qu JZ, Leung TY, Jiang P, Liao GJ, Cheng YK, Sun H, Chiu RW, Chan KC, Lo YM. Noninvasive prenatal determination of twin zygosity by maternal plasma DNA analysis. Clin Chem. 2013;59(2):427-35.

64. Society for Maternal-Fetal Medicine Publications Committee. Fetal Medicine Statement: clarification of recommendations regarding cell-free DNA aneuploidy screening. Am J Obstet Gynecol. 2015;213(6):753-4.